Serum sclerostin in alcoholics: a pilot study

Area of Science:

• Endocrinology
• Bone Biology
• Hepatology

Background:

• Sclerostin inhibits osteoblast activity, potentially contributing to decreased bone mass observed in alcoholism.
• The role of sclerostin in alcoholic patients with osteoporosis remains unclear.
• Alcohol abuse is a known risk factor for osteoporosis due to impaired bone synthesis.

Purpose of the Study:

• To investigate the relationship between serum sclerostin levels and bone mineral density (BMD) in alcoholic patients.
• To explore correlations between sclerostin, ethanol consumption, nutritional status, and liver function.
• To assess sclerostin's association with bone homeostasis biomarkers in alcoholism.

Main Methods:

• Cross-sectional study including 31 alcoholic patients (11 with Hepatitis C virus) and 7 controls.
• Bone mineral density (BMD) assessed via densitometry.
• Serum levels of sclerostin, osteocalcin, collagen telopeptide, PTH, vitamin D, cortisol, and testosterone were measured.

Main Results:

• Alcoholic patients exhibited significantly higher serum sclerostin levels compared to controls.
• Sclerostin showed an inverse correlation with osteocalcin and albumin, and a direct correlation with telopeptide and bilirubin.
• No significant correlation was found between sclerostin levels and BMD, nutritional status, or ethanol intake.

Conclusions:

• Serum sclerostin is elevated in alcoholic patients, reflecting disturbed bone turnover.
• The increase in sclerostin is associated with liver function derangement, not directly with ethanol consumption or nutritional status.
• These findings suggest sclerostin as a potential biomarker linked to liver dysfunction in alcoholic bone disease.